Iopromide is a non-ionic, iodinated radiographic contrast agent used in diagnostic imaging such as CT scans, angiography, and urography. It was developed in the 1980s and introduced into clinical use in the late 1980s to early 1990s, where it became widely adopted due to its improved safety profile and enhanced imaging quality compared to older high-osmolar contrast media. Its history is marked by its effectiveness in providing high-contrast radiographic visualization, but also by the recognition of potential adverse effects such as hypersensitivity reactions and contrast-induced nephrotoxicity, which led to careful patient screening and monitoring before administration. Iopromide is a low-osmolar, non-ionic contrast medium used in multiple imaging protocols and is included in a wide range of diagnostic radiology applications worldwide. Its development and clinical introduction were supported by extensive clinical trials and post-marketing surveillance programs to ensure safety, tolerability, and efficacy in diverse patient populations.
BRAND NAMES
Ultravist – the most widely recognized and globally used brand
Ultravist-300 – commonly used concentration variant
Ultravist-370 – higher iodine concentration used for enhanced vascular imaging.
MECHANISM OF ACTION
Iopromide is a non-ionic, water-soluble iodinated radiographic contrast agent that produces its imaging effect through physical enhancement of X-ray attenuation rather than biochemical interaction with receptors or enzymes. The iodine atoms within its structure have a high atomic number, which allows them to absorb X-rays efficiently.
PHARMACOKINETICS
Absorption
Iopromide is not absorbed in the conventional sense when administered intravenously, as it is directly introduced into the systemic circulation, resulting in immediate bioavailability.
Distribution
Iopromide has a low volume of distribution, typically close to the extracellular fluid volume (approximately 0.2–0.3 L/kg). It remains largely confined to the intravascular and interstitial spaces after intravascular administration and does not significantly penetrate into cells or cross intact biological barriers such as the blood–brain barrier.
Metabolism
Iopromide undergoes minimal to no metabolism in the human body. It remains largely unchanged after administration, as it is not significantly biotransformed by hepatic enzymes or other metabolic pathways.
Elimination
Iopromide is eliminated almost entirely by the kidneys through glomerular filtration in unchanged form. After intravascular administration, it is rapidly cleared from the bloodstream, with most of the dose excreted in urine within 24 hours in individuals with normal renal function.
PHARMACODYNAMICS
Iopromide does not produce pharmacological effects through receptors, enzymes, or biochemical signaling pathways. Instead, its pharmacodynamic action is purely physical, based on its ability to attenuate X-ray beams due to the high atomic number of iodine atoms within its structure.
ADMINISTRATION
Iopromide is administered under strict medical supervision in radiology settings, and the route depends on the diagnostic procedure being performed. It is most commonly given intravenously (IV) for contrast-enhanced CT scans and angiographic studies to visualize blood vessels and organs.
DOSAGE AND STRENGTH
Iopromide is supplied in different iodine concentration strengths, commonly expressed as 300 mg I/mL and 370 mg I/mL, with the choice of formulation depending on the imaging procedure and required level of contrast enhancement. The dosage is individualized based on the type of diagnostic study, route of administration, body weight, renal function, and clinical need.
DOSAGE AND STRENGTH
Iopromide is supplied in multiple iodine concentration strengths, most commonly 300 mg I/mL and 370 mg I/mL, with the selection depending on the imaging procedure and required level of contrast enhancement. The dose is individualized based on the type of diagnostic study, route of administration, patient body weight, renal function, and clinical indication.
DRUG INTERACTIONS
Iopromide has limited true pharmacokinetic drug–drug interactions because it is not metabolized and does not act on receptors. However, several clinically important interaction-related risks are recognized in practice.
FOOD INTERACTIONS
Iopromide has no clinically significant food–drug interactions, since it is an iodinated radiographic contrast agent that is not metabolized and does not interact with gastrointestinal absorption of nutrients. Food intake does not affect its distribution, imaging efficacy, or renal elimination when administered intravenously or intra-arterially.
CONTRAINDICATIONS
Iopromide is contraindicated in patients with a known history of hypersensitivity reactions to iopromide or other iodinated contrast media, particularly those who have experienced severe reactions such as anaphylaxis.
SIDE EFFECTS
Hypersensitivity reactions: rash, itching, urticaria
Severe allergic reactions (rare): anaphylactoid reactions, bronchospasm, angioedema
Feeling of warmth or flushing during injection
Nausea and vomiting
Headache or dizziness
Injection site reactions: pain, swelling, or irritation
Cardiovascular effects (rare): hypotension, tachycardia, arrhythmias.
OVER DOSE
Overdose of Iopromide is uncommon because it is administered in controlled radiology settings, but excessive doses or repeated rapid administration can increase the risk of toxicity. The main concern is contrast-induced nephrotoxicity, which may lead to acute kidney injury, reduced urine output, and elevated serum creatinine, especially in patients with pre-existing renal impairment, diabetes, or dehydration.
TOXICITY
Toxicity of Iopromide is primarily related to its iodine content, osmolar load, and patient-specific risk factors rather than direct intrinsic cellular toxicity. The most important toxic effect is contrast-induced nephrotoxicity, which can result in acute kidney injury, especially in patients with pre-existing renal impairment, diabetes mellitus, dehydration, or concurrent use of nephrotoxic drugs.
